Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate the safety and tolerability of locally
administered DLX105 in treating enterocutaneous fistulas in Crohn's Disease patients.
The study will consist of a screening period of approx. 2 weeks, a 4-week treatment period
and a 2-week follow-up period. An end-of study visit is scheduled on Day 43, 2 weeks after
the last study visit.